Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
Melanoma
DRUG: LXH254|DRUG: LTT462|DRUG: Trametinib|DRUG: Ribociclib
Overall Response Rate, Confirmed ORR using RECIST v1.1, per local assessment, 35 months
Duration of Reposnse (DOR), Local and central assessment, 4 years|Progression Free Survival (PFS), 4 years|Disease Control Rate (DCR), Using RECIST v1.1, per local and central assessment, 3 years|Overall Survival (OS), 4 years|Derived PK parameter (Cmax) for LXH254 & LTT462, Up to 5 months|Derived PK parameter (Cmax) for LXH254 & trametinib, Up to 5 months|Derived PK parameter (Cmax) for LXH254 & ribociclib, Up to 5 months|Derived PK parameter (AUC) for LXH254 & LTT462, Up to 5 months|Derived PK parameter (AUC) for LXH254 & trametinib, Up to 5 months|Derived PK parameter (AUC) for LXH254 & ribociclib, Up to 5 months|Incidence of adverse events (AEs) and serious adverse events (SAEs), Number of participants with Adverse Events (AEs) and SAEs as a measure of safety and tolerability, 35 months|Dose Interruptions, Tolerability measured by the number of subjects who have interruptions of study treatment and reason for interruptions, 35 months|Dose reductions, Tolerability measured by the number of subjects who have reductions of study treatment and reason for reductions, 35 months
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma